Oxytocin — questions, answered plainly.

Oxytocin is an endogenous nine-residue cyclic peptide hormone synthesised in the hypothalamus and released by the posterior pituitary. It plays peripheral roles (uterine contraction, milk ejection) and central roles (social bonding, anxiety, reward).

Synthetic oxytocin (Pitocin) is FDA-approved for the induction or augmentation of labour and the management of postpartum uterine atony. It is administered intravenously in hospital settings. The Robinson 2023 SOGC guideline (PMID 36725134) covers contemporary obstetric use.

Intranasal formulations of oxytocin are widely studied in psychiatric and behavioural-neuroscience contexts — particularly in autism spectrum research. Intranasal oxytocin is not FDA-approved for any psychiatric indication; published evidence is mixed.

Guastella et al. 2023 (Mol Psychiatry, PMID 36302965; n=87) was a double-blind RCT of intranasal oxytocin in young children with autism. The primary outcome (overall social responsiveness) did not reach statistical significance, though younger participants showed modest improvements.

Atosiban is an oxytocin-receptor antagonist used as a tocolytic agent for preterm labour in some jurisdictions. The Shubert 1995 review (PMID 8616970) covers its development and provides receptor-pharmacology context for understanding oxytocin agonism.

Oxytocin has extensive published literature (>30,000 PubMed records). The three citations on this profile are contemporary clinical-context anchors rather than a comprehensive field review. Off-label use should be discussed with a qualified clinician.